<DOC>
	<DOCNO>NCT02118311</DOCNO>
	<brief_summary>This Simon 's optimal two-stage phase II trial design estimate grade II-IV acute graft-versus-host disease ( GVHD ) infusion T regulatory ( nTreg ) fix dose ratio combine CD3+ cell count two graft unit recipient double UCB transplantation . The nTreg cell ( manufacture 3rd cord blood unit ) infuse day 0 least 1 hour 2nd unit double umbilical cord blood ( UCB ) transplant . The nTreg cell require 18 day ( ±2 day ) lead time base planned transplant day . The combined CD3+ cell content two graft UCB unit enumerate upon thaw ( day 0 ) . The patient receives number nTregs cell 3rd cord product achieve Treg : CD3+ cell ratio 5:1 . The nTreg cell dose depend CD3+ cell content two graft UCB graft unit , exceed high dose level safely test ongoing University Minnesota phase I Treg dose escalation study MT 2006-01 .</brief_summary>
	<brief_title>Treg Cells AGVHD Non-myeloablative UCB Transplant</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Must ≥18 , &lt; 70 year age match 5/6 6/6 sibling donor patient ≥ 70 ≤ 75 year age may eligible CoMorbidity score ≤ 2 ( Appendix II ) Three UCB unit compose graft select accord current University Minnesota umbilical cord blood graft selection algorithm . Each UCB unit must match 46 HLAA , B , DRB1 antigens recipient . This may include 02 antigen mismatch A B DRB1 locus . Each unit must 46 HLAA , B , DRB1 antigen match , necessarily loci matched recipient . Disease Criteria Acute Leukemias : Must remission morphology ( &lt; 5 % blast ) . Note cytogenetic relapse persistent disease without morphologic relapse acceptable . Also small percentage blast equivocal marrow regeneration versus early relapse acceptable provide associate cytogenetic marker consistent relapse . Acute Lymphoblastic Leukemia ( ALL ) first complete remission ( CR1 ) NOT consider favorablerisk define presence least one following : Adverse cytogenetics ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL rearrangements White blood cell count great 30,000/mcL ( BALL ) great 100,000/mcL ( TALL ) diagnosis Recipient age old 30 year diagnosis Time CR great 4 week Acute Myelogenous Leukemia ( AML ) first complete remission ( CR1 ) NOT consider favorablerisk . Favorable risk define one following : ( 8,21 ) without CKIT mutation inv ( 16 ) without CKIT mutation ( 16 ; 16 ) Normal karyotype mutate NPM1 FLTIND Normal karyotype double mutate CEBPA APL first molecular remission end consolidation Acute Leukemias 2nd subsequent CR Biphenotypic/Undifferentiated first subsequent CR , adult Tcell leukemia/lymphoma first subsequent complete remission ( CR ) Burkitt 's Lymphoma CR2 subsequent complete remission ( CR ) Natural Killer Cell Malignancies Chronic Myelogenous Leukemia : type except refractory blast crisis . Chronic phase patient must fail intolerant least one tyrosinekinase inhibitor Myelodysplastic Syndrome : subtype include refractory anemia ( RA ) severe pancytopenia complex cytogenetics . Blasts must less 5 % . If 5 % require induction therapy pretransplant reduce blast count ≤5 % . LargeCell Lymphoma , Hodgkin Lymphoma Multiple Myeloma chemotherapy sensitive disease fail patient ineligible autologous transplant . Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ( CLL/SLL ) , Marginal Zone BCell Lymphoma , Follicular Lymphoma , progress within 12 month achieve partial complete remission . Patients remission last &gt; 12 month , eligible least two prior therapy . Patients bulky disease consider debulking chemotherapy transplant . Patients refractory disease eligible , unless bulky disease estimate tumor double time le one month . Lymphoplasmacytic Lymphoma , MantleCell Lymphoma , Prolymphocytic Leukemia eligible initial therapy chemotherapy sensitive . Patients must undergone autologous transplant ≤ 12 month prior allogeneic transplantation receive multiagent immunosuppressive chemotherapy within 3 month preparative regimen . Adequate performance status define Karnofsky score ≥ 70 % Adequate organ function within 14 day ( 30 day cardiac pulmonary ) enrollment define : Renal : creatinine &lt; 2.0 mg/dL , patient creatinine &gt; 1.2 mg/dL history renal dysfunction estimate glomerular filtration rate &gt; 40 mL/min/1.73 m2 require Hepatic : bilirubin , AST , ALT , alkaline phosphatase &lt; 5 x upper limit normal , Pulmonary function : DLCOcorr &gt; 40 % normal , Cardiac : leave ventricular ejection fraction &gt; 35 % Voluntary write consent sign performance studyrelated procedure part normal medical care Untreated active infection time transplantation History HIV infection Pregnant breast feeding . The agent use study may teratogenic fetus information excretion agent breast milk . Females childbearing potential must blood test urine study within 14 day prior registration rule pregnancy Prior allogeneic transplantation Less 3 month myeloablative condition autologous transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acute Leukemias</keyword>
	<keyword>Burkitt 's Lymphoma</keyword>
	<keyword>Natural Killer Cell Malignancies</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Large-Cell Lymphoma</keyword>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Marginal Zone B-Cell Lymphoma</keyword>
	<keyword>Follicular Lymphoma :</keyword>
	<keyword>Lymphoplasmacytic Lymphoma</keyword>
	<keyword>Mantle-Cell Lymphoma</keyword>
	<keyword>Prolymphocytic Leukemia</keyword>
</DOC>